Charcot's foot: newest findings on its pathophysiology, diagnosis and treatment.

Charcot neuro-osteoarthropathy (CNO) is one of the more devastating complications affecting diabetic patients with peripheral and/or autonomic neuropathy. The acute phase of the disease is often misdiagnosed, and can rapidly lead to deformity and amputation. The rapid progression towards foot deformation calls for early detection and intervention. Classical neurotraumatic and neurotrophic theories fail to explain all of the features of the condition, although recent advances that have clarified the mechanisms underlying the pathophysiology may make up for this lack. In particular, new data have emerged on the central role of the RANK/RANK-ligand (RANK-L)/osteoprotegerin (OPG) system in the pathogenesis of osteopenia. Also, it is now recognized that the acute phase of CNO can be triggered by any factor leading to local inflammation of the foot, especially in predisposed patients. As the cornerstone of treatment remains any method that avoids weight-bearing on the foot, the primary importance of the RANK/RANK-L/OPG signalling pathway is that it opens up the field to new treatment strategies for the future.

[1]  W. Jeffcoate.  Vascular calcification and osteolysis in diabetic neuropathy—is RANK-L the missing link? , 2004, Diabetologia.

[2]  S. Horibe,et al.  Neuroarthropathy of the foot in leprosy. , 1988, The Journal of bone and joint surgery. British volume.

[3]  N. Maalouf,et al.  The Role of Receptor Activator of Nuclear Factor-κB (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications , 2007 .

[4]  S. Sinha,et al.  NEURO-ARTHROPATHY (CHARCOT JOINTS) IN DIABETES MELLITUS , 1972 .

[5]  C. Brown,et al.  Charcot Restraint Orthotic Walker , 1998, Foot & ankle international.

[6]  W. R. Jordan.  NEURITIC MANIFESTATIONS IN DIABETES MELLITUS , 1936 .

[7]  R. Jenkins,et al.  Charcot neuroarthropathy in diabetes mellitus , 2002, Diabetologia.

[8]  L. Poll,et al.  Evaluation of the diabetic charcot foot by MR imaging or plain radiography--an observational study. , 2006, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[9]  A. Jirkovska,et al.  Intranasal Calcitonin in the Treatment of Acute Charcot Neuroosteoarthropathy , 2006, Diabetes Care.

[10]  W. Jeffcoate.  Charcot neuro‐osteoarthropathy , 2008, Diabetes/metabolism research and reviews.

[11]  P. Sheehan,et al.  Vincristine-induced neuroarthropathy (Charcot's joint) , 2000, Journal of the American Podiatric Medical Association.

[12]  M. Clouse,et al.  Diabetic osteoarthropathy. Clinical and roentgenographic observations in 90 cases. , 1974, The American journal of roentgenology, radium therapy, and nuclear medicine.

[13]  B. Erol,et al.  Conservative treatment of Charcot artroparthy in a series of spina bifida patients: the experience of one center and review of the literature , 2007, Journal of pediatric orthopedics. Part B.

[14]  M. Reiser,et al.  Magnetic resonance imaging in early stage charcot arthropathy: correlation of imaging findings and clinical symptoms. , 2008, European journal of medical research.

[15]  J. Mitchell.  On a New Practice in Acute and Chronic Rheumatism , 1831, The London medical and physical journal.

[16]  F. Logerfo.  The high risk foot in diabetes mellitus , 1992 .

[17]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[18]  A. Manto,et al.  Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. , 2005, Diabetes care.

[19]  W. Jeffcoate,et al.  Medial arterial calcification in diabetes and its relationship to neuropathy , 2009, Diabetologia.

[20]  R. Frykberg,et al.  Management of the diabetic Charcot foot , 2000, Diabetes/metabolism research and reviews.

[21]  E. Trepman,et al.  Current Practice Patterns in the Treatment of Charcot Foot , 2000, Foot & ankle international.

[22]  J. Thomson,et al.  Charcot arthropathy in spina bifida. , 2000, Journal of pediatric orthopedics.

[23]  N. Maalouf,et al.  The Role of Receptor Activator of Nuclear Factor-B ( RANK ) / RANK Ligand / Osteoprotegerin : Clinical Implications , 2007 .

[24]  F. Alvine,et al.  Treatment of Diabetic Foot Ulcers and Charcot Neuroarthropathy Using the Patellar Tendon-Bearing Brace , 1997, Foot & ankle international.

[25]  D. M. van der Heijde,et al.  Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. , 2008, Arthritis and rheumatism.

[26]  D. Armstrong,et al.  Healing Rates of Diabetic Foot Ulcers Associated with Midfoot Fracture Due to Charcot’s Arthropathy , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[27]  W. F. Todd,et al.  The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[28]  C. Saltzman,et al.  Pneumatic Bracing and Total Contact Casting Have Equivocal Effects on Plantar Pressure Relief , 2001, Foot & ankle international.

[29]  Nagarkatti Dg,et al.  Charcot arthropathy in spina bifida. , 2000 .

[30]  W. F. Todd,et al.  The Natural History of Acute Charcot’s Arthropathy in a Diabetic Foot Specialty Clinic , 1997, Journal of the American Podiatric Medical Association.

[31]  D. Sinacore.  Acute Charcot arthropathy in patients with diabetes mellitus: healing times by foot location. , 1998, Journal of diabetes and its complications.

[32]  A. M. Foster,et al.  Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial , 2001, Diabetologia.

[33]  M. Edmonds,et al.  Increased osteoclastic activity in acute Charcot’s osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand , 2008, Diabetologia.

[34]  M. Boninger,et al.  Use of bivalved ankle-foot orthosis in neuropathic foot and ankle lesions. , 1996, Journal of rehabilitation research and development.

[35]  F. Zaccardi,et al.  Association Between Osteoprotegerin G1181C and T245G Polymorphisms and Diabetic Charcot Neuroarthropathy , 2009, Diabetes Care.

[36]  P. Watkins,et al.  Increased uptake of bone radiopharmaceutical in diabetic neuropathy. , 1985, The Quarterly journal of medicine.

[37]  W. Jeffcoate,et al.  The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes , 2005, The Lancet.

[38]  G. Rümenapf,et al.  Diabetische neuropathische Osteoarthropathie (Charcot-Fuß) , 2003 .

[39]  M. McGill,et al.  Response of Charcot's arthropathy to contact casting: assessment by quantitative techniques , 2000, Diabetologia.

[40]  J. S. San Martin,et al.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.

[41]  J. Baumhauer,et al.  Cytokine-Induced Osteoclastic Bone Resorption in Charcot Arthropathy: An Immunohistochemical Study , 2006, Foot & ankle international.

[42]  Vera Ai,et al.  Charcot foot in an alcoholic patient. A case report. , 1995 .

[43]  S. Sinha,et al.  Neuro-arthropathy (Charcot joints) in diabetes mellitus (clinical study of 101 cases). , 1972, Medicine.

[44]  J. Charcot.  Sur quelques arthropathies qui paraissent dépendre d'une lésion du cerveau ou de la moelle épinière , 1868 .

[45]  B. Nixon,et al.  Charcot foot in an alcoholic patient. A case report. , 1995, Journal of the American Podiatric Medical Association.